science

Pneumococcal polysaccharide vaccine

Pneumococcal polysaccharide vaccine is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Pneumococcal polysaccharide vaccine rather than just read about it. In short: Pneumococcal polysaccharide vaccine, sold under the brand name Pneumovax 23, is a pneumococcal vaccine that is used for the prevention of pneumococcal disease caused by the 23 serotypes of Streptococcus pneumoniae contained in the vaccine as capsular polysaccharides. It is given by intramuscular or subcutaneous injection.

Key takeaways

Pneumococcal polysaccharide vaccine belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Pneumococcal polysaccharide vaccine to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Pneumococcal polysaccharide vaccine from memory before moving on to harder problems.

Reference excerpt

Pneumococcal polysaccharide vaccine, sold under the brand name Pneumovax 23, is a pneumococcal vaccine that is used for the prevention of pneumococcal disease caused by the 23 serotypes of Streptococcus pneumoniae contained in the vaccine as capsular polysaccharides. It is given by intramuscular or subcutaneous injection. The polysaccharide antigens were used to induce type-specific antibodies that enhanced opsonization, phagocytosis, and killing of Streptococcus pneumoniae (pneumococcal) bacteria by phagocytic immune cells. The pneumococcal polysaccharide vaccine is widely used in high-risk adults. First used in 1945, the tetravalent vaccine was not widely distributed, since its deployment coincided with the discovery of penicillin. In the 1970s, Robert Austrian championed the manufacture and distribution of a 14-valent pneumococcal polysaccharide vaccine. This evolved in 1983 to a 23-valent formulation (PPSV23). A significant breakthrough affecting the burden of pneumococcal disease was the licensing of a protein conjugate heptavalent vaccine (PCV7) beginning in February 2000.

Medical uses In the United States, pneumococcal vaccine, polyvalent is indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). It is approved for use in people 50 years of age or older and people aged two years of age or older who are at increased risk for pneumococcal disease. The World Health Organization (WHO) recommendations are similar. The WHO does not recommend use of pneumococcal polysaccharide vaccine in routine childhood immunization programs. The recommendations in the UK are similar, but include people with occupational hazards. Pneumococcal vaccine may be beneficial to control exacerbations of chronic obstructive pulmonary disease (COPD). The pneumococcal polysaccharide vaccine is important for those with HIV/AIDS. In Canadian patients infected with HIV, the vaccine has been reported to decrease the incidence of invasive pneumococcal disease from 768 per 100,000 person–years to 244 per 100,000 patient–years. Because of the low level of evidence for benefit, 2008 WHO guidelines do not recommend routine immunization with PPV-23 for HIV patients, and suggests preventing pneumococcal disease indirectly with trimethoprim–sulfamethoxazole chemoprophylaxis and antiretrovirals. While the U.S. Centers for Disease Control and Prevention (CDC) recommends immunization in all patients infected with HIV.

Adverse events The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).

Vaccination schedule

Adults and children over two years of age The 23-valent vaccine (for example, Pneumovax 23) is effective against 23 different pneumococcal capsular types (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F), and so covers 90 percent of the types found in pneumococcal bloodstream infections.

Young children Children under the age of two years fail to mount an adequate response to the 23-valent adult vaccine, and instead a multi-valent pneumococcal conjugate vaccine (for example, PCV13: Prevnar 13 or PCV21: Capvaxive) is used instead. The first of these was the PCV7 (Prevnar 7), and in 2010, the PCV13 replaced the PCV7, adding six new serotypes to the vaccine. While this covers only thirteen strains out of more than ninety strains, these thirteen strains caused 80–90 percent of cases of severe pneumococcal disease in the U.S. before introduction of the vaccine, and it is considered to be nearly 100 percent effective against these strains. As of 2025, a 15-valent, and later 20-valent (PCV20: Prevnar 20) successors to the Prevnar 13 have been introduced, in addition to the introduction of an 21-valent vaccine (PCV21: Capvaxive) not directly derived from the Prevnar series.. The PCV20 supersedes the PCV15, PCV13, and PCV7, but the PCV21 contains 11 serotypes not covered by the PCV20, and the distinct mechanism of the PPSV23 means it may be indicated in different circumstances than the conjugate vaccines. The PPSV23 additionally contains 2 serotypes not contained in the PCV20 but contained within the PCV21, and 2 serotypes contained within neither; the remaining 19 serotypes overlap the PCV20, notwithstanding the PCV21.

Special risk-groups Children at special risk (e.g., sickle cell disease and those without a functioning spleen) require additional protection using the PCV13, with the more extensive PPSV-23 given after the second year of life or two months after the PCV13 dose:

References

Illustrations

Worked examples

Example 1 — a first encounter with Pneumococcal polysaccharide vaccine

Start with the simplest possible case. Write down what Pneumococcal polysaccharide vaccine claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Pneumococcal polysaccharide vaccine before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Pneumococcal polysaccharide vaccine ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Pneumococcal polysaccharide vaccine

In research: Pneumococcal polysaccharide vaccine appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Pneumococcal polysaccharide vaccine in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Pneumococcal polysaccharide vaccine is common in secondary-school and first-year university syllabi. It links to neighbouring topics Vaccines, so understanding it makes those chapters shorter.
In everyday life: Look for Pneumococcal polysaccharide vaccine outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Pneumococcal polysaccharide vaccine” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Pneumococcal polysaccharide vaccine in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Pneumococcal polysaccharide vaccine means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Pneumococcal polysaccharide vaccine out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Pneumococcal polysaccharide vaccine in simple terms?

Why does Pneumococcal polysaccharide vaccine matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Pneumococcal polysaccharide vaccine?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Pneumococcal polysaccharide vaccine.